## **Behavioral Health: Early Intervention for Youth**

Please put your name and organization into the chat 3.13.24



### Agenda



- Welcome
- Minutes
- Bree Areas of Influence
- Review Levels of Prevention & Early Intervention
- Defining Parameters
- Focus Areas
- Public Comment, Closing and Next Steps

#### Minutes



#### Bree Collaborative | Behavioral Health Early Interventions for Youth

February 14<sup>th</sup>, 2024 | 8-9:30AM **Hybrid** 

#### MEMBERS PRESENT VIRTUAL

Kevin Mangat, MHA, Navos

Terry Lee, MD, CHPW (Chair)
Linda Coombs, MSW, LICSWUHC
Thatcher Felt, DO, YVFWC
Jeffery Greene, MD Seattle Children's
Nicole Hamberger, SWACH
Libby Hein, LMHC, Molina

Mckenna Parnes, PhD, University of Washington Sarah Rafton, MSW, WCAAP Brittany Weiner, LMFT, CPPS; WSHA Jennifer Wyatt, LMHC, MAC, SUDP with KingCou nty Behavioral Health and Recovery Division

#### STAFF AND MEMBERS OF THE PUBLIC

Beth Bojkov, MPH, RN, Bree Collaborative Emily Nudelman, DNP, RN, Bree Collaborative Karie Nicholas, MA, GC, Bree Collaborative

### **Bree Areas of Influence**



#### **Bree Collaborative Stakeholders**




- Direct line of implementation: anyone involved in the clinical interaction or in the billing process
  - Reports are sent to the Washington HCA for consideration for inclusion in their contracts
  - Other lines of implementation being explored,
- Clinicians/Healthcare Professionals
- Healthcare Delivery Systems (e.g., pediatric primary care, hospitals, etc)
  - Increasingly school-based health clinics
  - Home-based services
- Health Plans
- Purchasers

## Level of Prevention & Early Intervention



#### Colizzi et al,





#### **Levels of Prevention**



- Primary prevention
  - Universal prevention (pr-clinical stage): interventions aimed at promoting normal neurodevelopment
  - Selective prevention (clinical stage 0): interventions aimed at preventing manifestation of psychiatric symptoms, thus altering developmental pathway to full-threshold disorders in premorbid state
  - Indicated prevention (clinical stage 1): indicated interventions aimed at identification of those individuals at high clinical risk for development of a mental disorder who are functionally impaired and no longer asymptomatic
- Secondary prevention (clinical stage 2): aim at mitigating the occurrence of negative prognostic factors such as long duration of untreated illness, poor treatment response, poor psychosocial well-being and functioning and comorbid substance use and high burden on patients' families with final goal of preventing relapse or incomplete recovery

### **Defining Scope Parameters**



#### **Defining Parameters**



- Settings:
  - Primary Care,
  - School-based Care
- Age:
  - Should we use Age/Grade?
    - USPSTF: start BH screening at 12 years old
    - WHO: adolescence defined as 10-19
    - Bright Futures screening at 12 years old
    - Healthy Youth Survey starts in 6<sup>th</sup> grade (11-12)
- Primary Diagnoses: (Depression, Anxiety, Trauma/PTSD), (Disruptive Behavior & Substance Use)
  - 20% of Washington adolescents 12-17 will have major depressive episode in any given year (SAMHSA)
  - 33% increase in the rate of students reporting depression and anxiety since 2010 (UW SMART Center)
  - Grade 12 Past 30-day substance use in 2021 was 20% for alcohol, 16% for marijuana, and 2% prescription drugs not prescribed (WA Healthy Youth Survey)
- Outside scope: primary diagnosis of suicide, autism, eating disorders, sleep care, etc.

#### **Defining Parameters**



- Severity: mild-moderate
  - Those displaying symptoms/functionally impaired without a diagnosis
  - Those with diagnosis with mild/moderate symptoms and functional impairment
- What are we defining as a crisis?
  - Defined by the parents or system (primary pediatric care, school& school-based) that are unable to handle the youth's needs
  - Immediate threat to self or others (plans for suicide, self harms thoughts, thoughts or plan of harming others) (Seattle Children's)
  - Any situation in which a person's behavior puts them at risk of hurting themselves or others and/or
    prevents them from being able to care for themselves or function effectively in the community. (NAMI)
  - 988: those at risk for suicide as well as those experiencing other mental health and substance use related emergencies

#### **Potential Top Goal**



•Increase availability and access to high quality indicated and secondary prevention behavioral health interventions for youth

### **Focus Areas**

YBH Draft Focus Areas.docx



# Closing: Public Comment & Next Steps



## Public Comment



### **Public Comment**



#### **Next Steps**



- Next meeting April 10<sup>th</sup>, 2024 8-9:30AM HYBRID
- Forward contact information to <a href="mailto:bree@qualityhealth.org">bree@qualityhealth.org</a> or <a href="mailto:ebojkov@qualityhealth.org">ebojkov@qualityhealth.org</a> for potential speakers
- Finish OPMA training/Conflict of Interest forms and return to <a href="mailto:bree@qualityhealth.org">bree@qualityhealth.org</a> or <a href="mailto:ebojkov@qualityhealth.org">ebojkov@qualityhealth.org</a>
- Creating shared Google drive for resources/research of interest

#### **Upcoming Events and Opportunities**



## Health Equity Action Collaborative



#### About the Action Collaborative

Join Bree Collaborative Staff as a participant in the Health Equity Action Collaborative! During the collaborative, participants will receive support in taking their chosen health project from an idea to developing an implementation plan that can be enacted within their organization. Health equity will be centered in the design process through education, discussion, and peer engagement. The action collaborative is open to individuals working within the healthcare ecosystem (clinicians, delivery sites, QI teams, purchasers, plans, etc.) interested in improving health outcomes while promoting equitable practices.